凌科药业递表港交所

Group 1 - The core viewpoint of the news is that LYNK Pharmaceuticals Co., Ltd. has submitted an application to list on the Hong Kong Stock Exchange, indicating its growth and expansion plans in the pharmaceutical industry [1] - LYNK Pharmaceuticals is positioned as a leading pharmaceutical company in China with a global focus, dedicated to developing innovative drugs for the treatment of tumors, immune, and inflammatory diseases [1] - The company was founded by experienced drug development experts who have accumulated decades of experience in drug discovery [1] Group 2 - The company has demonstrated exceptional efficiency in advancing its product development pipeline, with significant progress on its core products LNK01001 and LNK01004 [1] - The first candidate product is expected to enter the preclinical stage, while the VAVI project has progressed to supportive research for new drug clinical trials [1]